Piramal Pharma Q1 Consolidated Net Loss Narrows to ₹69.4 Crore as Revenue Rises to ₹2,270 Crore

Market snapshot: Piramal Pharma Limited announced a significant operational turnaround for the first quarter ended June 30, 2026 (Q1 FY27). The company reported robust double-digit top-line growth across all three core segments, helping to narrow consolidated net losses year-on-year. Strong execution and higher operating leverage driven by scaling overseas operations led to substantial operating margin expansion.

Data Snapshot

• Consolidated Revenue from Operations grew 17.39% YoY to ₹2,269.92 crore from ₹1,933.71 crore in Q1 FY26.
• Consolidated Net Loss narrowed by 15.06% YoY to ₹69.39 crore compared with a net loss of ₹81.70 crore in the same period last year.
• Operating EBITDA (Operating Profit) surged 82.24% YoY to ₹195.20 crore from ₹107.03 crore in Q1 FY26.
• Operating EBITDA Margin expanded by 308 basis points YoY to 8.60% from 5.52% in Q1 FY26.
• Standalone Revenue from Operations climbed 15.99% YoY to ₹1,124.95 crore from ₹969.88 crore.

What's Changed

• Consolidated net loss improved YoY, reducing by 15.06% to ₹69.39 crore from ₹81.70 crore.
• Consolidated operating revenue climbed to ₹2,269.92 crore, up 17.39% YoY.
• Operating EBITDA surged by 82.24% to ₹195.20 crore, reflecting strong operating turnaround.
• EBITDA margin expanded significantly by 308 basis points YoY to 8.60% from 5.52%.

Key Takeaways

• The CDMO segment delivered 19% YoY growth to ₹1,187 crore, supported by broad-based performance across India and overseas sites and robust order inflows.
• Complex Hospital Generics (CHG) segment reported 17% growth to ₹743 crore, maintaining leadership in key anesthesia markets.
• Piramal Consumer Healthcare (PCH) revenue grew 15% YoY to ₹347 crore, driven by a 23% expansion in Power Brands.
• Management confirmed that the Sellersville US facility successfully completed its US FDA inspection, receiving an EIR with Zero OAI status.

SAHI Perspective

Piramal Pharma is demonstrating a clear structural turnaround with all three key business segments delivering double-digit revenue growth. The sharp operating margin expansion to 8.60% (and 12.5% under the company's internal reporting definitions) indicates that capacity utilization is rising and cost-optimization efforts are yielding results. While net profitability remains negative due to scaling and finance costs, the operational recovery is firmly established.

Market Implications

The narrowing of consolidated losses and double-digit revenue expansion will be viewed positively by the street as a sign of cyclical recovery in the CDMO space. The successful clearing of the Sellersville US FDA audit enhances compliance visibility, while the upcoming commercial contribution from the Kenalog® portfolio starting Q2 FY27 provides an incremental growth catalyst.

Trading Signals

Market Bias: Bullish

The strong 17.39% YoY revenue growth and 82.24% surge in operating EBITDA indicate robust operational momentum. Margin expansion of 308 bps to 8.60% shows improving operating leverage, confirming the structural business turnaround is on track.

Overweight: Pharmaceuticals, CDMO, Healthcare

Trigger Factors:

• First full-quarter commercial contribution from the Kenalog® acquisition starting Q2 FY27.
• Stabilization and resumption of manufacturing at the Ahmedabad SEZ facility following localized flooding.
• Sustainable improvement in the US biotech funding landscape to drive CDMO order conversions.

Time Horizon: Medium-term (3–12 months)

Industry Context

The global CDMO and contract research sector is seeing a progressive recovery from previous headwinds of customer inventory destocking and high inflation. Piramal Pharma's performance signals that global biopharma demand is returning, specifically for specialized CDMO capabilities like antibody-drug conjugates (ADCs) and sterile injectables where the company has directed its capital investments.

Key Risks to Watch

• Volatility in the effective tax rate, which management expects to remain elevated in FY27 before normalizing to 24%-25% as international operations scale.
• Decision-making cycles for CDMO customers remain elongated, which could delay order book execution.
• Localized disruptions, such as the temporary manufacturing suspension at the Ahmedabad facility due to flooding, although the site contributes less than 3% to consolidated sales.

Recent Developments

On July 24, 2026, Piramal Pharma temporarily suspended manufacturing operations at its PHARMEZ SEZ facility in Ahmedabad, Gujarat, due to severe flooding. Separately, on July 29, 2026, the company announced that its Sellersville facility in the United States successfully cleared its US FDA audit, receiving an EIR with Zero OAI observations.

Closing Insight

Piramal Pharma is progressively shaking off historical CDMO destocking and capacity-underutilization headwinds. Although elevated tax rates continue to delay bottom-line profitability, the core operating divisions are performing strongly, establishing a highly resilient platform for the quarters ahead.

High Performance Trading with SAHI.